FDA provides guidance on clinical pathway to marketing application for Revascor in end-stage heart failure patients with an LVAD
Melbourne Australia; 27 August 2019, and New York, USA, 26 August 2019 Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, announced today positive outcomes from its recent meeting with the United States Food and…
IDT Secures its first Medicinal Cannabis Manufacturing Permit from the Office of Drug Control
27 August 2019 IDT Australia Limited (ASX: IDT) is pleased to announce that the Department of Health – Office of Drug Control has granted the Company its first Medicinal Cannabis Manufacturing Permit under the Narcotic Drugs Act 1967.…
Positive results with Targeted DEP® using antibody fragment in human ovarian cancer model – Starpharma
29 August 2019 Melbourne, Australia: Starpharma today announced that treatment with a novel HER-2 Targeted DEP® conjugate from its internal Targeted DEP® program resulted in tumour regression and 100% survival in a preclinical human ovarian cancer model. This finding builds on…
Next step in Alzheimer’s disease treatment – SVI & Janssen Pharmaceucticals Inc
29 August 2019 SVI has announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, Inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, with focus on Alzheimer’s disease treatment. The objective of…
Melbourne provides a spark for Israeli tech startup SparkBeyond
29 August 2019 Israeli tech startup company SparkBeyond has chosen Melbourne – Australia’s Tech City – for its first office in the country. Founded in 2013, SparkBeyond has built an artificial intelligence (AI) powered data analytics and problem…
The Australian PBS approves Mayne Pharma’s Kapanol morphine drug for reimbursement
29 August 2019 Mayne Pharma says the Australian Pharmaceutical Benefits Scheme has approved its Kapanol morphine drug for palliative care chronic breathlessness for reimbursement. Mayne Pharma said that from September 1, 2019 eligible palliative care patients taking 10mg…
Efficacy signals have been observed in Starpharma’s clinical trials of dendrimer enhanced product (DEP) cabazitaxel and docetaxel
29 August 2019 Starpharma said both DEP-cabazitaxel and DEP-docetaxel had been showing “promising interim results”, with several patients dosed with DEP-cabazitaxel showing efficacy signals in tumors including prostate, ovarian and pancreatic cancer. In January 2018, Starpharma said it…
Bluechiip revenue for FY19 up 82.5%
29 August 2019 Bluechiip says revenue for the year to June 30, 2019 was up 82.5 percent to a record $1,025,052 with net loss after tax up 30.7 percent to $3,257,996. Bluechiip said revenue was from sales of…
Noxopharm’s NOX66 reduces tumor size and pain in patient study for prostate cancer
29 August 2019 Noxopharm says interim three-month results of its 11-patient study of Veyonda or NOX66 with radiotherapy for prostate cancer has reduced tumor size and pain. Noxopharm said it administered a single, 15-day course of 1,200mg of…
Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
27 August 2019 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production.…
Nucleus Network expansion creates first global, multi-site early phase trial organisation with investment in USA-based phase I clinical trials organization, Prism Clinical Research.
27 August, 2019 Nucleus Network, Australia’s leading early-phase clinical research organization, is pleased to announce it has acquired a majority shareholding in Prism Clinical Research, a 52-bed, early-phase clinical research facility located in Minneapolis/St. Paul, Minnesota, USA. The…
NOX receives 2018/19 Federal Government R&D tax rebate
23 August 2019 Sydney, Australia. Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Officer, said,…
